Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 631 to 640 of 2208 total matches.

Which PPI?

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
Which PPI? An article published in the New York Times on May 1, 2015 listed the 10 drugs on which ...
An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor (PPI) Nexium (esomeprazole magnesium), which has recently become available generically.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):91 | Show Introduction Hide Introduction

Droxidopa (Northera) for Neurogenic Orthostatic Hypotension

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
used (off-label) to treat symptomatic NOH include fludrocortisone and pyridostigmine.1 MECHANISM ...
The FDA has approved droxidopa (Northera – Lundbeck) for oral treatment of adults with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or nondiabetic autonomic neuropathy. This is the first approval for droxidopa in the US. It has been available in Japan for use in NOH since 1989.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):92-3 | Show Introduction Hide Introduction

Bellafill for Acne Scars

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
12 months.1 ADVERSE EFFECTS — Swelling, redness, pain, bruising, lumps/bumps, itching ...
Bellafill (Suneva), a dermal filler approved earlier for correction of nasolabial folds, has now also been approved by the FDA for correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in adults ≥21 years old. It is the only dermal filler approved in the US for correction of facial acne scars.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):93-4 | Show Introduction Hide Introduction

In Brief: Ketoacidosis with SGLT2 Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
) inhibitor for treatment of type 2 diabetes may lead to ketoacidosis.1 Three SGLT2 inhibitors ...
The FDA has warned that use of an SGLT2 (sodium-glucose co-transporter 2) inhibitor for treatment of type 2 diabetes may lead to ketoacidosis.1 Three SGLT2 inhibitors, canagliflozin (Invokana, Invokamet), dapagliflozin (Farxiga, Xigduo XR), and empagliflozin (Jardiance, Glyxambi), are approved for treatment of type 2 diabetes in the US. Between March 2013 and June 2014, 20 cases of ketoacidosis requiring emergency room visits or hospitalization were reported in patients who had recently started taking an SGLT2 inhibitor; the median time to onset of symptoms after initiation of therapy was 2...
Med Lett Drugs Ther. 2015 Jun 22;57(1471):94 | Show Introduction Hide Introduction

Addendum: Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
) was published in the most recent issue of The Medical Letter (June 8, 2015),1 some new data became available ...
After our article on nivolumab (Opdivo – BMS) for treatment of metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) was published in the most recent issue of The Medical Letter (June 8, 2015),1 some new data became available supporting the efficacy of the drug in previously untreated melanoma and previously treated nonsquamous NSCLC.MELANOMA – In a double-blind trial, 945 patients with previously untreated, unresectable stage III or IV melanoma were randomized to receive ipilimumab, nivolumab, or combination therapy with ipilimumab and nivolumab. Progression-free...
Med Lett Drugs Ther. 2015 Jun 22;57(1471):94 | Show Introduction Hide Introduction

Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015  (Issue 1470)
death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma ...
The FDA has approved nivolumab (Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda), and the first to be approved for treatment of NSCLC.
Med Lett Drugs Ther. 2015 Jun 8;57(1470):85-7 | Show Introduction Hide Introduction

Recombinant Human Parathyroid Hormone (Natpara)

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015  (Issue 1470)
serum calcium, parathyroid hormone binds to PTH-1 receptors both in bone, causing release of calcium ...
The FDA has approved a subcutaneously injected formulation of recombinant human parathyroid hormone (Natpara – NPS) as an adjunct to calcium and vitamin D to control hypocalcemia in adults with hypoparathyroidism. Natpara is an 84-amino acid single-chain polypeptide identical to native parathyroid hormone. It is the first parathyroid hormone formulation to be approved for this indication.
Med Lett Drugs Ther. 2015 Jun 8;57(1470):87-8 | Show Introduction Hide Introduction

Ivabradine (Corlanor) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
not reduce mortality.1 MECHANISM OF ACTION — Ivabradine slows heart rate by inhibiting the cardiac ...
The FDA has approved ivabradine (Corlanor – Amgen) to reduce the risk of hospitalization for worsening heart failure in adults with stable, symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≤35% who are in sinus rhythm with a resting heart rate ≥70 beats per minute and who are on maximum tolerated doses of beta blockers or have a contraindication to beta blocker use. Ivabradine has been available internationally for years as Procoralan and Corlentor for treatment of stable angina and heart failure.
Med Lett Drugs Ther. 2015 May 25;57(1469):75-6 | Show Introduction Hide Introduction

Fluticasone Furoate (Arnuity Ellipta) for Asthma

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.1 Pronunciation Key Fluticasone furoate: floo ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Med Lett Drugs Ther. 2015 May 25;57(1469):76-9 | Show Introduction Hide Introduction

Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
– Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.1 ...
The FDA has approved ceftazidime/avibactam (Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam (Zerbaxa – Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.
Med Lett Drugs Ther. 2015 May 25;57(1469):79-80 | Show Introduction Hide Introduction